Biopharmaceutical company Hansa Medical AB (STO:HMED) reported on Wednesday net loss of SEK176.6m, or SEK4.97 per share, for 2017, from January 2017 to December 2017.
This was a decline over net loss of SEK111.13m, or SEK3.37 per share, in 2016.
Net revenues for the year were SEK3,442,000, as compared with SEK2.579m in 2016.
Hansa Medical is developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead product, IdeS, is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications.
(EUR1.00=SEK9.9)
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Perrigo to pay quarterly dividend of USD0.290 per share
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline